EMA Withdrawn: Irbesartan BMS (irbesartan) — Bristol-Myers Squibb Pharma EEIG

View source ↗

Summary

The EMA withdrew the irbesartan product Irbesartan BMS (irbesartan) from Bristol-Myers Squibb Pharma EEIG, affecting its hypertension therapy indication.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• Irbesartan BMS (irbesartan)

Snippet

Status: Withdrawn. Therapeutic area: Hypertension. MAH: Bristol-Myers Squibb Pharma EEIG. Decision date: 07/04/2009